New precursor cells are found to be able to produce new HSPCs

Recently, researchers at the Icahn School of Medicine at Mount Sinai found some cells in mouse embryos based on previous work. These cells are hematopoietic stem cells or precursor cells of hematopoietic stem cells / progenitor cells (HSPCs). In previous studies, they reprogrammed mouse skin cells as HSPCs in the laboratory. Now, they have identified progenitor cells in a mouse embryo and placenta and the cell can mature and produce HSPCs in the laboratory. Their findings were entitled "Hematopoietic Reprograming in Vitro Informs in Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells" and published in the journal Developmental Cell on March 7th, indicating that this reprogrammed process can repeatedly function during blood cell development. These results may eventually prompted researchers to prepare patient-specific HSPCs and bring more differentiation of blood products for cell replacement therapy.

Patients who suffer from blood diseases (such as leukemia, lymphoma, and multiple myeloma) and people with compromised immune systems are in great demand for transplantable stem cells. Researchers are exploring an approach that can produce large amount of HSPCs in the laboratory and the method of preparing patient-specific HSPCs. The reprogramming process developed by the researchers at Icahn School of Medicine at Mount Sinai seems to mimic the normal blood's function of cell production or developmental hematopoiesis - from precursor cells eventually become HSPCs cells. This technology shows the potential to provide a different source of stem cells and alleviate the needs of transplant.

The research team analyzed the embryo and placenta of mice to explore whether there are certain cells which has a similar phenotype as precursor cells do and confirmed that they can mature into HSPCs in the laboratory.

Senior author of the study, associate professor at Mount Sinai School of Medicine, Developmental and Regenerative Biology Icahn Kateri Moore pointed out, "In the long run, in order to cure the disease, we need to be able to transplant something which can continue to produce new blood cells but not rejected by the patient's body. We are excited about the results of this study. In the laboratory, these precursor cells can grow to HSPCs which can be portable. Our reprogramming process can inform the development of hematopoiesis, and vice versa."

Other members of the research team include Dr. Ihor Lemischka Developmental and Regenerative Biology professor, author, former postdoctoral researcher at Mount Sinai School of Medicine, Icahn Biology Dr. Carlos-Filipe Pereira. He is currently an assistant professor at the University of Coimbra.

Dr. Lemischka said, "Direct reprogramming research could improve the applications of regenerative medicine. We have 20 years of research and experience in the field of hematopoietic stem cell biology. Our ultimate goal is to prepare into blood cells in the laboratory and increased productivity of patient-specific blood cells. This study makes us closer to achieving this goal."

Go through this link: http://www.cusabio.com/Polyclonal-Antibody/SLC34A2-Antibody-FITC-conjugated--11106194.html